PubAg

Main content area

Canine myxosarcomas, a retrospective analysis of 32 dogs (2003–2018)

Author:
Iwaki, Yoshimi, Lindley, Stephanie, Smith, Annette, Curran, Kaitlin M., Looper, Jayme
Source:
BMC veterinary research 2019 v.15 no.1 pp. 217
ISSN:
1746-6148
Subject:
dogs, drug therapy, histopathology, lungs, lymph nodes, metastasis, mitosis, nonsteroidal anti-inflammatory agents, prognosis, radiotherapy, resection, retrospective studies, risk, sarcoma, tissues
Abstract:
BACKGROUND: Myxosarcomas are known to be classified as soft tissue sarcomas. However, there is limited clinical characterization pertaining specifically to canine cutaneous myxosarcomas in the literature. The objective of this study is to evaluate the local recurrence rate, metastatic rate and prognosis of canine myxosarcoma. RESULTS: A total of 32 dogs diagnosed with myxosarcoma via histopathology were included in this retrospective study. All dogs had surgical resection. No adjunct treatments were performed in 9 dogs, while 22 dogs also received either radiation therapy or chemotherapy, or a combination of both. One dog received only NSAID after surgery. Overall median survival time (MST) was 730 days (range 20–2345 days). The MST of dogs with a tumor mitotic count < 10/10 HPF was 1393 days (range 20–2345 days). The dogs with a tumor mitotic count of 10 or greater/10 HPF had a MST of 433 days (range 169–831 days). There was no significant difference of MST among different treatment modalities. Local recurrence was noted in 13 cases (40.6%) and the median time to recurrence was 115.5 days (range 50–1610 days). The median time to local recurrence in dogs with mitotic count of < 10/10 HPF was 339 days (range 68–1610 days) and in dogs with mitotic count of 10 or greater/10 HPF was 119 days (range 50–378). Metastasis to local lymph node or lung was noted in 8 cases (25%) with median time to metastasis of 158.5 days (range 0–643 days). CONCLUSIONS: Based on the results of this retrospective study, myxosarcoma may have a higher local recurrence rate and risk of metastasis to the local lymph nodes compared to other soft tissue sarcomas.
Agid:
6487911